Drug intelligence / Profile preview

[11C]leucine

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[11C]leucine is a radiolabeled amino acid used as a positron emission tomography (PET) tracer for the quantitative measurement of regional rates of cerebral protein synthesis in vivo. The compound consists of the essential amino acid leucine labeled with the positron-emitting isotope carbon-11. After intravenous administration, [11C]leucine crosses the blood-brain barrier and is incorporated into proteins during protein synthesis. PET imaging with [11C]leucine enables non-invasive assessment of brain protein metabolism and has been used in research on neurodegenerative diseases such as Alzheimer's disease and in studies investigating memory formation. The mechanism involves uptake by amino acid transporters followed by incorporation into newly synthesized proteins, allowing quantification of protein synthesis rates in specific brain regions[4][6][8].

Other names
carbon-11 leucinecarbon11 leucinecarbon 11 leucineC-11 leucineC11 leucineC 11 leucineL-leucine (carbon-11 labeled)1-[11C]leucine
02

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)aaRS (Aminoacyl-tRNA synthetase family)RibosomeNeuraminidaseLAT (Linker for activation of T cells)

Beyond the preview

Go deeper on [11C]leucine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]leucine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call